Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

“Unweaving the rainbow of prostate cancer spatial heterogeneity”


MA(Oxon), MBChB, PhD(Cantab), FRCS(Urol) Alastair Lamb - Cancer Research UK Clinician Scientist, SPACE Group LeaderMr Alastair Lamb is a Consultant Urological surgeon with particular expertise in prostate cancer and robotic surgery. He works as an Honorary Consultant Urologist at the Churchill Hospital Cancer Centre and is a Cancer Research UK Clinician scientist fellow at the Nuffield Department of Surgical Sciences. 

His research goal is to provide a robust molecular platform for accurate decision-making in early-stage prostate cancer. He has spent his scientific training investigating how individual genes or groups of genes have driven prostate cancer behaviour. His PhD thesis investigated the role of HES6 as a transcriptional driver in castrate resistant prostate cancer – we found that this single gene fundamentally changed the nature of prostate cancer cells. During this time, he was funded by the Cambridge Biomedical Research Centre (NIHR) and GlaxoSmithKline, and also by a Raymond and Beverly Sackler Studentship. Subsequently, he developed an interest in integrated genomics in prostate cancer risk stratification as well as disease modelling with patient derived xenografts. In October 2018, he commenced a five-year Cancer Research UK funded Clinician Scientist Fellowship to undertake the SPACE Study, a translational research programme centred on identification the ‘lethal clone’ in high risk localised prostate cancer incorporating integrated genomics of targeted biopsies, spatial transcriptomics of whole prostates and data-driven tracking of clonal phylogenetics including in micro-metastatic disease. He also has an interest in novel molecular imaging techniques such as PSMA PET-CT and their use in disease stratification and decision-making before, during and after radical therapies. He is co-chief investigator of the TRANSLATE Trial and a local investigator for the PROMOTE, PART & FINESSE trials as well as TROMBONE which is now closed. 


Chair: Professor Ashok Handa

All members of the University and NHS clinical staff are welcome.

Please email Louise King if you would like to attend.